MarketCap
Facebook
X
Telegram
Mustang Bio ROCE Ratio | MBIO
Annual ROCE Ratio Mustang Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -25.13 | 492.12 | -2077.6 | -98.51 | -58.35 | -56.59 | -69.87 | -31.91 | -26.27 | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 492.12 | -2077.6 | -216.9 |
Quarterly ROCE Ratio Mustang Bio
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -49.93 | -40.51 | -54.4 | -49.04 | -11.3 | 13.56 | 157.99 | 348.53 | -50.95 | -230.54 | -431.51 | -642.1 | -298.57 | -157.33 | -88.14 | -76.92 | -69.38 | -63.35 | -57.45 | -53.05 | -56.11 | -55.66 | -59.45 | -60.0 | -63.59 | -63.19 | -60.68 | -68.66 | -76.32 | -80.27 | -78.51 | -70.44 | -64.8 | -58.84 | -56.97 | -49.81 | -55.8 | -51.79 | -47.88 | -46.81 | 5.87 | 28.68 | -3.39 | 20.42 | 15.94 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 348.53 | -642.1 | -68.05 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Forward Pharma A/S
FWP
|
-5.47 | - | -0.75 % | $ 18.7 M |  Danmark |
 |
Orchard Therapeutics plc
ORTX
|
-129.33 | - | 1.02 % | $ 90.8 M |  Britain |
 |
La Jolla Pharmaceutical Company
LJPC
|
-32.71 | - | - | $ 154 M |  USA |
 |
Oyster Point Pharma
OYST
|
-97.1 | - | - | $ 300 M | USA |
 |
Nabriva Therapeutics plc
NBRV
|
-1333.89 | - | - | $ 4.55 M |  Irlanda |
 |
Intercept Pharmaceuticals
ICPT
|
-20.32 | - | - | $ 643 M | USA |
 |
NGM Biopharmaceuticals
NGM
|
-101.9 | - | - | $ 127 M | USA |
 |
Regulus Therapeutics
RGLS
|
-65.49 | - | - | $ 155 M | USA |
 |
9 Meters Biopharma
NMTR
|
-1750.31 | - | -42.97 % | $ 1.05 M | USA |
 |
Chinook Therapeutics
KDNY
|
-41.88 | - | - | $ 2.6 B | USA |
 |
Lumos Pharma
LUMO
|
-134.09 | - | - | $ 35.3 M | USA |
 |
Syros Pharmaceuticals
SYRS
|
-774.14 | - | -8.44 % | $ 3.4 M | USA |
 |
NanoViricides
NNVC
|
-95.66 | $ 1.32 | 2.33 % | $ 26.6 M | USA |
 |
Gamida Cell Ltd.
GMDA
|
-46.52 | - | -18.25 % | $ 5.04 M |  Israel |
 |
GT Biopharma
GTBP
|
-214.65 | $ 4.42 | -2.64 % | $ 24.4 M | USA |
 |
Aravive
ARAV
|
-664.7 | - | -13.39 % | $ 1.45 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-883.35 | - | -74.18 % | $ 955 K | USA |
 |
Omeros Corporation
OMER
|
101.29 | $ 16.91 | -1.11 % | $ 1.07 B | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
19.81 | $ 14.9 | 2.58 % | $ 12.4 B |  India |
 |
C4 Therapeutics
CCCC
|
-35.34 | $ 3.09 | 4.75 % | $ 256 M | USA |
|
Phathom Pharmaceuticals
PHAT
|
-125.87 | $ 5.24 | 3.05 % | $ 382 M | USA |
 |
Protalix BioTherapeutics
PLX
|
-9.85 | $ 2.51 | 1.0 % | $ 197 M | Israel |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
-51.28 | $ 4.8 | 4.35 % | $ 40.9 M | USA |
 |
PTC Therapeutics
PTCT
|
44.91 | $ 65.94 | 0.41 % | $ 5.24 B | USA |
 |
Celldex Therapeutics
CLDX
|
-54.02 | $ 29.89 | 5.71 % | $ 1.99 B | USA |
 |
Pulmatrix
PULM
|
-35.98 | $ 1.42 | 1.36 % | $ 5.19 B | USA |
 |
Arcus Biosciences
RCUS
|
-61.17 | $ 18.27 | 3.28 % | $ 1.96 B | USA |
 |
Sana Biotechnology
SANA
|
-74.02 | $ 2.41 | 2.99 % | $ 610 M | USA |
 |
Vir Biotechnology
VIR
|
-52.67 | $ 12.27 | 11.34 % | $ 1.7 B | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
19.16 | $ 547.4 | 0.9 % | $ 140 B | USA |
 |
vTv Therapeutics
VTVT
|
-39.41 | $ 20.85 | -4.09 % | $ 82.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Eli Lilly and Company
LLY
|
21.04 | $ 1 363.22 | -0.33 % | $ 1.22 T | USA |
 |
Compugen Ltd.
CGEN
|
23.38 | $ 1.97 | 2.6 % | $ 184 M | Israel |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-141.54 | $ 3.94 | 2.79 % | $ 48.1 M | Israel |
 |
Edesa Biotech
EDSA
|
-63.54 | $ 2.19 | 2.67 % | $ 12.4 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
5.3 | $ 62.15 | -1.6 % | $ 126 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
95.22 | $ 14.49 | 4.4 % | $ 937 M | USA |
 |
Moderna
MRNA
|
-35.54 | $ 253.93 | 5.17 % | $ 98.8 B | USA |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
-34.24 | $ 1.55 | -9.36 % | $ 1.04 B | Israel |
 |
Achieve Life Sciences
ACHV
|
-90.77 | $ 6.75 | 5.8 % | $ 294 M | USA |
 |
Amgen
AMGN
|
104.87 | $ 460.27 | 0.28 % | $ 248 B | USA |
 |
Armata Pharmaceuticals
ARMP
|
16.76 | $ 3.37 | 12.33 % | $ 122 M | USA |
 |
Axsome Therapeutics
AXSM
|
-53.63 | $ 132.34 | 1.95 % | $ 6.58 B | USA |
|
Champions Oncology
CSBR
|
-28.94 | $ 4.8 | 0.85 % | $ 66.4 M | USA |
|
Forte Biosciences
FBRX
|
-115.85 | $ 76.99 | 0.03 % | $ 997 M | USA |
 |
Immunic
IMUX
|
1572.16 | $ 7.79 | 6.42 % | $ 1.21 B | USA |
 |
AC Immune SA
ACIU
|
-116.39 | $ 2.23 | 5.69 % | $ 225 M |  Schweiz |
 |
Aldeyra Therapeutics
ALDX
|
-79.69 | $ 0.64 | 4.12 % | $ 38.4 M | USA |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M |  Canada |